

# Bernard Le Le Foll

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5461752/publications.pdf>

Version: 2024-02-01

253  
papers

11,835  
citations

25034

57  
h-index

36028

97  
g-index

284  
all docs

284  
docs citations

284  
times ranked

10499  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined effect of alcohol and cannabis on simulated driving. <i>Psychopharmacology</i> , 2022, 239, 1263-1277.	3.1	15
2	3-Year Follow-up of Lower Risk Cannabis Use Patterns: Evidence from a Longitudinal Survey. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 48-56.	1.9	3
3	The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics. <i>Revista Brasileira De Psiquiatria</i> , 2022, 44, 81-93.	1.7	2
4	Clinical management of cannabis withdrawal. <i>Addiction</i> , 2022, 117, 2075-2095.	3.3	28
5	Evaluating the effectiveness of bupropion and varenicline for smoking cessation using an internet-based delivery system: A pragmatic randomized controlled trial (MATCH study). <i>Drug and Alcohol Dependence</i> , 2022, 232, 109312.	3.2	7
6	Tobacco and nicotine use. <i>Nature Reviews Disease Primers</i> , 2022, 8, 19.	30.5	67
7	Medical Cannabis and Past-Year Cannabis Use Disorder Among Adult Recreational Users in the United States: Results From a Nationally Representative Sample. <i>Frontiers in Psychiatry</i> , 2022, 13, 836908.	2.6	3
8	Repetitive Transcranial Magnetic Stimulation for Comorbid Major Depressive Disorder and Alcohol Use Disorder. <i>Brain Sciences</i> , 2022, 12, 48.	2.3	6
9	A Historical Perspective on the Dopamine D3 Receptor. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 1-28.	1.7	1
10	Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. <i>Neuropsychopharmacology</i> , 2022, 47, 1315-1330.	5.4	28
11	Neurochemical Alterations in Social Anxiety Disorder (SAD): A Systematic Review of Proton Magnetic Resonance Spectroscopic Studies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4754.	4.1	4
12	Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 118, 110570.	4.8	6
13	Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 169-191.	1.7	2
14	Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial. <i>Addiction</i> , 2022, 117, 2662-2672.	3.3	6
15	Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 726-739.	7.2	23
16	Quantifying GABA in Addiction: A Review of Proton Magnetic Resonance Spectroscopy Studies. <i>Brain Sciences</i> , 2022, 12, 918.	2.3	9
17	Opioid-sparing effects of cannabinoids: Myth or reality?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 106, 110065.	4.8	12
18	Perioperative Pain and Addiction Interdisciplinary Network (PAIN): consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users by a modified Delphi process. <i>British Journal of Anaesthesia</i> , 2021, 126, 304-318.	3.4	31

#	ARTICLE	IF	CITATIONS
19	Cannabinoid Drugs in Mental Health Disorders. , 2021, , 1-35.		0
20	Association of the Fatty Acid Amide Hydrolase C385A Polymorphism With Alcohol Use Severity and Coping Motives in Heavyâ€Drinking Youth. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 507-517.	2.4	11
21	Cannabis use and cannabis use disorder. <i>Nature Reviews Disease Primers</i> , 2021, 7, 16.	30.5	179
22	Integrating a brief alcohol intervention with tobacco addiction treatment in primary care: qualitative study of health care practitioner perceptions. <i>Addiction Science &amp; Clinical Practice</i> , 2021, 16, 17.	2.6	9
23	Significant association of nicotine reinforcement and cue reactivity: a translational study in humans and rats. <i>Behavioural Pharmacology</i> , 2021, 32, 212-219.	1.7	5
24	Impact of CYP2A6 Activity on Nicotine Reinforcement and Cue-Reactivity in Daily Smokers. <i>Nicotine and Tobacco Research</i> , 2021, 23, 1735-1743.	2.6	7
25	The influence of conditioned stimuli on [11C]-(+)-PHNO PET binding in tobacco smokers after a one week abstinence. <i>Scientific Reports</i> , 2021, 11, 11667.	3.3	2
26	Influence of Cannabinoid Receptor 1 Genetic Variants on the Subjective Effects of Smoked Cannabis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7388.	4.1	6
27	Canadian Society of Transplantation White Paper: Ethical and Legal Considerations for Alcohol and Cannabis Use in Solid Organ Listing and Allocation. <i>Transplantation</i> , 2021, 105, 1957-1964.	1.0	6
28	Exploring regulation and function of dopamine D3 receptors in alcohol use disorder. A PET [11C]-(+)-PHNO study. <i>Neuropsychopharmacology</i> , 2021, 46, 2112-2120.	5.4	5
29	Reviewing pharmacogenetics to advance precision medicine for opioids. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112060.	5.6	14
30	The CB1R rs2023239 receptor gene variant significantly affects the reinforcing effects of nicotine, but not cue reactivity, in human smokers. <i>Brain and Behavior</i> , 2021, 11, e01982.	2.2	6
31	Abnormalities of Neurotransmission in Drug Addiction. , 2021, , 653-712.		2
32	Pharmacological Treatment of Alcohol Use Disorder. , 2021, , 123-139.		0
33	MR Spectroscopy of the Insula: Within- and between-Session Reproducibility of MEGA-PRESS Measurements of GABA+ and Other Metabolites. <i>Brain Sciences</i> , 2021, 11, 1538.	2.3	3
34	Imaging Histamine H3 Receptors with Positron Emission Tomography. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , .	1.7	0
35	Monitoring the impact of Cannabis Use. <i>Trends in Psychiatry and Psychotherapy</i> , 2021, , .	0.8	1
36	Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review. <i>Pharmaceuticals</i> , 2021, 14, 1316.	3.8	11

#	ARTICLE	IF	CITATIONS
37	The complexity of pharmacology of cannabidiol (CBD) and its implications in the treatment of brain disorders. <i>Neuropsychopharmacology</i> , 2020, 45, 229-230.	5.4	18
38	Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults. <i>Psychopharmacology</i> , 2020, 237, 305-316.	3.1	75
39	The effect of pre-existing alcohol use disorder on the risk of developing posttraumatic stress disorder: results from a longitudinal national representative sample. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 232-240.	2.1	20
40	D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction. <i>Neuropsychopharmacology</i> , 2020, 45, 745-752.	5.4	12
41	The effects of dopamine D4 receptor ligands on operant alcohol self-administration and cue- and stress-induced reinstatement in rats. <i>European Journal of Pharmacology</i> , 2020, 867, 172838.	3.5	11
42	Melatonin for Treatment-Seeking Alcohol Use Disorder patients with sleeping problems: A randomized clinical pilot trial. <i>Scientific Reports</i> , 2020, 10, 8739.	3.3	10
43	Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. <i>International Journal of Clinical Practice</i> , 2020, 75, e13871.	1.7	26
44	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. <i>Drug and Alcohol Dependence</i> , 2020, 212, 107993.	3.2	49
45	Acute and residual mood and cognitive performance of young adults following smoked cannabis. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 194, 172937.	2.9	18
46	Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence. <i>Cells</i> , 2020, 9, 1196.	4.1	26
47	Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs. <i>Biomolecules</i> , 2020, 10, 855.	4.0	24
48	Safety and Efficacy of Varenicline for Smoking Cessation in Alcohol-Dependent Smokers in Concurrent Treatment for Alcohol Use Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 130-136.	1.4	11
49	Exploring the role of the Ser9Gly (rs6280) Dopamine D3 receptor polymorphism in nicotine reinforcement and cue-elicited craving. <i>Scientific Reports</i> , 2020, 10, 4085.	3.3	11
50	Personalized dosing of nicotine replacement therapy versus standard dosing for the treatment of individuals with tobacco dependence: study protocol for a randomized placebo-controlled trial. <i>Trials</i> , 2020, 21, 592.	1.6	2
51	Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB. <i>Neuropsychopharmacology</i> , 2020, 45, 1289-1296.	5.4	28
52	Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET. <i>British Journal of Pharmacology</i> , 2020, 177, 3464-3472.	5.4	15
53	Pharmacotherapies for cannabis dependence. <i>The Cochrane Library</i> , 2020, 2020, CD008940.	2.8	35
54	Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1065-1080.	5.0	9

#	ARTICLE	IF	CITATIONS
55	Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 82-87.	1.9	15
56	A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study. <i>Addiction</i> , 2019, 114, 1095-1109.	3.3	160
57	Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. <i>Handbook of Experimental Pharmacology</i> , 2019, 258, 355-372.	1.8	5
58	Psychosocial and Pharmacological Interventions for the Treatment of Cannabis Use Disorder. <i>Focus (American Psychiatric Publishing)</i> , 2019, 17, 163-168.	0.8	5
59	Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade. <i>Handbook of Experimental Pharmacology</i> , 2019, 258, 395-420.	1.8	5
60	Nicotine Self-Administration as Paradigm for Medication Discovery for Smoking Cessation: Recent Findings in Medications Targeting the Cholinergic System. <i>Methods in Molecular Biology</i> , 2019, 2011, 165-193.	0.9	1
61	Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 167, 25-75.	1.7	87
62	Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107641.	3.2	44
63	The effect of a clinical decision support system on prompting an intervention for risky alcohol use in a primary care smoking cessation program: a cluster randomized trial. <i>Implementation Science</i> , 2019, 14, 85.	6.9	9
64	Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. <i>Cmaj</i> , 2019, 191, E1049-E1056.	2.0	62
65	Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans. <i>Neuropsychopharmacology</i> , 2019, 44, 1284-1290.	5.4	13
66	The Insula: A Brain Stimulation Target for the Treatment of Addiction. <i>Frontiers in Pharmacology</i> , 2019, 10, 720.	3.5	69
67	Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review. <i>Frontiers in Psychiatry</i> , 2019, 10, 98.	2.6	20
68	Polydrug use disorders in individuals with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2019, 198, 28-33.	3.2	72
69	Tobacco and Positron-Emission Tomography (PET) of the Dopaminergic System: A Review of Human Studies. , 2019, , 107-117.		2
70	Transcriptomic Characterization of the Human Insular Cortex and Claustrum. <i>Frontiers in Neuroanatomy</i> , 2019, 13, 94.	1.7	12
71	Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 342-350.	6.1	34
72	Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 37-43.	0.3	14

#	ARTICLE	IF	CITATIONS
73	The Human Laboratory and Drug Development in Alcohol Use Disorder: Recent Updates. <i>Methods in Molecular Biology</i> , 2019, 2011, 195-219.	0.9	5
74	Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.. <i>Experimental and Clinical Psychopharmacology</i> , 2019, 27, 359-369.	1.8	24
75	The Rat Gambling Task as a model for the preclinical development of treatments for gambling disorder. <i>International Gambling Studies</i> , 2018, 18, 217-241.	2.1	1
76	The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. <i>Contemporary Clinical Trials</i> , 2018, 69, 21-27.	1.8	22
77	Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 503-512.	2.1	9
78	A method for co-creation of an evidence-based patient workbook to address alcohol use when quitting smoking in primary care: a case study. <i>Research Involvement and Engagement</i> , 2018, 4, 4.	2.9	11
79	Longitudinal alcohol consumption patterns and health-related quality of life: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. <i>Drug and Alcohol Review</i> , 2018, 37, 48-55.	2.1	15
80	Preliminary evaluation of a human laboratory model of impaired control over alcohol using intravenous alcohol self-administration. <i>Journal of Psychopharmacology</i> , 2018, 32, 105-115.	4.0	10
81	Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels. <i>Psychopharmacology</i> , 2018, 235, 23-35.	3.1	12
82	Deep TMS of the insula using the H-coil modulates dopamine release: a crossover [11C] PHNO-PET pilot trial in healthy humans. <i>Brain Imaging and Behavior</i> , 2018, 12, 1306-1317.	2.1	41
83	Improvement of the association between self-reported pill count and varenicline levels following exclusion of participants with misreported pill count: A commentary on Peng et al. (2017). <i>Addictive Behaviors</i> , 2018, 79, 14-16.	3.0	4
84	Transcriptomic Characterization of the Human Habenula Highlights Drug Metabolism and the Neuroimmune System. <i>Frontiers in Neuroscience</i> , 2018, 12, 742.	2.8	23
85	Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPAR $\alpha$ agonist) in smokers. <i>PLoS ONE</i> , 2018, 13, e0201512.	2.5	12
86	Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. <i>F1000Research</i> , 2018, 7, 173.	1.6	19
87	Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 793-804.	2.5	9
88	Outcomes of an integrated care pathway for concurrent major depressive and alcohol use disorders: a multisite prospective cohort study. <i>BMC Psychiatry</i> , 2018, 18, 189.	2.6	10
89	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. <i>PLoS ONE</i> , 2018, 13, e0190768.	2.5	88
90	When and How to Treat Possible Cannabis Use Disorder. <i>Medical Clinics of North America</i> , 2018, 102, 667-681.	2.5	7

#	ARTICLE	IF	CITATIONS
91	Varenicline and Bupropion for Long-Term Smoking Cessation (the MATCH Study): Protocol for a Real-World, Pragmatic, Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e10826.	1.0	11
92	Studying the Role of D 4 Receptors in Psychiatric Illnesses and Related Functions With L-745,870. , 2018, , ,		0
93	A Preliminary Investigation of the Effect of Acute Alcohol on Dopamine Transmission as Assessed by [ <sup>11</sup> C]-(+)-PHNO. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1112-1119.	2.4	7
94	Investigating the effects of norepinephrine $\alpha$ 1 receptor blockade on dopamine levels: A pilot PET study with [ <sup>11</sup> C]-(+)-PHNO in controls. <i>Synapse</i> , 2017, 71, e21968.	1.2	2
95	A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 197-214.	2.1	15
96	The endocannabinoid system as a target for addiction treatment: Trials and tribulations. <i>Neuropharmacology</i> , 2017, 124, 73-83.	4.1	77
97	Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. <i>Neuropsychopharmacology</i> , 2017, 42, 1752-1765.	5.4	190
98	A 35-year-old woman with low mood and concerns about her alcohol use. <i>Cmaj</i> , 2017, 189, E317-E318.	2.0	1
99	Corticotropin-releasing hormone and dopamine release in healthy individuals. <i>Psychoneuroendocrinology</i> , 2017, 76, 192-196.	2.7	20
100	The effects of buspirone on occupancy of dopamine receptors and the rat gambling task. <i>Psychopharmacology</i> , 2017, 234, 3309-3320.	3.1	14
101	The effect of post-traumatic stress disorder on the risk of developing prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. <i>Drug and Alcohol Dependence</i> , 2017, 179, 260-266.	3.2	52
102	Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis. <i>American Journal on Addictions</i> , 2017, 26, 551-563.	1.4	18
103	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. <i>American Journal of Public Health</i> , 2017, 107, 1277-1277.	2.7	25
104	Impairment of Neuroplasticity in the Dorsolateral Prefrontal Cortex by Alcohol. <i>Scientific Reports</i> , 2017, 7, 5276.	3.3	19
105	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. <i>American Journal of Public Health</i> , 2017, 107, e1-e12.	2.7	295
106	Combining alcohol interventions with tobacco addictions treatment in primary care—the COMBAT study: a pragmatic cluster randomized trial. <i>Implementation Science</i> , 2017, 12, 65.	6.9	7
107	The dopamine D3 receptor, a quarter century later. <i>European Journal of Neuroscience</i> , 2017, 45, 2-19.	2.6	178
108	The Role of the Endocannabinoid System in Addiction. , 2017, , 187-236.		2

#	ARTICLE	IF	CITATIONS
109	Integrated care pathway for co-occurring major depressive and alcohol use disorders: Outcomes of the first two years. <i>American Journal on Addictions</i> , 2017, 26, 602-609.	1.4	10
110	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [ <sup>11</sup> C]CURB. <i>Biological Psychiatry</i> , 2016, 80, 691-701.	1.3	53
111	What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses. <i>Progress in Brain Research</i> , 2016, 224, 419-447.	1.4	5
112	Screening Medications for the Treatment of Cannabis Use Disorder. <i>International Review of Neurobiology</i> , 2016, 126, 87-120.	2.0	13
113	Effects of varenicline on motor cortical plasticity in non-smokers with schizophrenia. <i>Schizophrenia Research</i> , 2016, 178, 50-55.	2.0	2
114	The agranular and granular insula differentially contribute to gambling-like behavior on a rat slot machine task: effects of inactivation and local infusion of a dopamine D4 agonist on reward expectancy. <i>Psychopharmacology</i> , 2016, 233, 3135-3147.	3.1	22
115	The CB <sub>1</sub> Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw068.	2.1	58
116	Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence. <i>Journal of Addiction Medicine</i> , 2016, 10, 274-279.	2.6	32
117	Psychosocial interventions for cannabis use disorder. <i>The Cochrane Library</i> , 2016, , CD005336.	2.8	141
118	Effects of various cannabinoid ligands on choice behaviour in a rat model of gambling. <i>Behavioural Pharmacology</i> , 2016, 27, 258-269.	1.7	12
119	Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats. <i>Psychopharmacology</i> , 2016, 233, 1823-1828.	3.1	27
120	Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys. <i>Neuropsychopharmacology</i> , 2016, 41, 2283-2293.	5.4	54
121	Brain Stimulation in Alcohol Use Disorders: Investigational and Therapeutic Tools. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016, 1, 5-13.	1.5	10
122	Alcohol Intoxication by Binge Drinking Impairs Neuroplasticity. <i>Brain Stimulation</i> , 2016, 9, 27-32.	1.6	16
123	Impact of short access nicotine self-administration on expression of $\alpha 4\beta 2^*$ nicotinic acetylcholine receptors in non-human primates. <i>Psychopharmacology</i> , 2016, 233, 1829-1835.	3.1	8
124	Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. <i>Drug and Alcohol Dependence</i> , 2016, 161, 298-306.	3.2	70
125	Neuronal calcium sensor-1 deletion in the mouse decreases motivation and dopamine release in the nucleus accumbens. <i>Behavioural Brain Research</i> , 2016, 301, 213-225.	2.2	31
126	Effect of a D3 receptor antagonist on context-induced reinstatement of nicotine seeking. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 149-154.	4.8	12



#	ARTICLE	IF	CITATIONS
127	Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self-administration and relapse in squirrel monkeys. <i>Psychopharmacology</i> , 2016, 233, 1791-1800.	3.1	29
128	Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice. <i>Psychopharmacology</i> , 2016, 233, 1815-1822.	3.1	19
129	Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [ <sup>11</sup> C]-(+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2016, 41, 1513-1520.	5.4	18
130	Occupancy of Dopamine D3 and D2 Receptors by Bupirone: A [ <sup>11</sup> C]-(+)-PHNO PET Study in Humans. <i>Neuropsychopharmacology</i> , 2016, 41, 529-537.	5.4	24
131	Evaluating the Impact of Naltrexone on the Rat Gambling Task to Test Its Predictive Validity for Gambling Disorder. <i>PLoS ONE</i> , 2016, 11, e0155604.	2.5	14
132	Major depression and suicide attempts in patients with liver disease in the United States. <i>Liver International</i> , 2015, 35, 1910-1916.	3.9	36
133	Screening and Treatment for Alcohol, Tobacco and Opioid Use Disorders: A Survey of Family Physicians across Ontario. <i>PLoS ONE</i> , 2015, 10, e0124402.	2.5	14
134	Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with <sup>11</sup> 9-Tetrahydrocannabinol. <i>PLoS ONE</i> , 2015, 10, e0144270.	2.5	104
135	Psychiatric Disorders as Vulnerability Factors for Nicotine Addiction: What Have We Learned from Animal Models?. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 24, 155-170.	1.7	8
136	Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States. <i>Accident Analysis and Prevention</i> , 2015, 76, 1-5.	5.7	45
137	Involvement of the rostral agranular insular cortex in nicotine self-administration in rats. <i>Behavioural Brain Research</i> , 2015, 290, 77-83.	2.2	48
138	Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction. <i>European Neuropsychopharmacology</i> , 2015, 25, 1401-1409.	0.7	14
139	The Fatty Acid Amide Hydrolase C385A Variant Affects Brain Binding of the Positron Emission Tomography Tracer [ <sup>11</sup> C]CURB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1237-1240.	4.3	58
140	Role of the endogenous cannabinoid system in nicotine addiction: novel insights. <i>Frontiers in Psychiatry</i> , 2015, 6, 41.	2.6	48
141	Cannabinoids: Friend or foe?. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 528-531.	4.7	8
142	Differential Involvement of the Agranular vs Granular Insular Cortex in the Acquisition and Performance of Choice Behavior in a Rodent Gambling Task. <i>Neuropsychopharmacology</i> , 2015, 40, 2832-2842.	5.4	31
143	Development and Implementation of an Ambulatory Integrated Care Pathway for Major Depressive Disorder and Alcohol Dependence. <i>Psychiatric Services</i> , 2015, 66, 1265-1267.	2.0	8
144	Involvement of the caudal granular insular cortex in alcohol self-administration in rats. <i>Behavioural Brain Research</i> , 2015, 293, 203-207.	2.2	36

#	ARTICLE	IF	CITATIONS
145	Investigation of the genetic interaction between <i>BDNF</i> and <i>DRD3</i> genes in suicidal behaviour in psychiatric disorders. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 171-179.	2.6	14
146	The Impact of Selective Dopamine D2, D3 and D4 Ligands on the Rat Gambling Task. <i>PLoS ONE</i> , 2015, 10, e0136267.	2.5	28
147	CHAPTER 4. The Self-medication Hypothesis in Schizophrenia: What Have We Learned from Animal Models?. <i>RSC Drug Discovery Series</i> , 2015, , 70-88.	0.3	0
148	Off-Label Use of Medications for Treatment of Benzodiazepine Use Disorder. <i>Current Pharmaceutical Design</i> , 2015, 21, 3306-3310.	1.9	1
149	Increased collision risk among drivers who report driving after using alcohol and after using cannabis. <i>Canadian Journal of Public Health</i> , 2014, 105, e92-e93.	2.3	8
150	Dopamine D3 Receptor Is Necessary for Ethanol Consumption: An Approach with Buspirone. <i>Neuropsychopharmacology</i> , 2014, 39, 2017-2028.	5.4	52
151	Alcohol inhalation. <i>Cmaj</i> , 2014, 186, E399-E399.	2.0	3
152	Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development. <i>Frontiers in Pharmacology</i> , 2014, 5, 161.	3.5	38
153	The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. <i>Psychological Medicine</i> , 2014, 44, 797-810.	4.5	434
154	Elevation of Dopamine Induced by Cigarette Smoking: Novel Insights from a [ <sup>11</sup> C]-(+)-PHNO PET Study in Humans. <i>Neuropsychopharmacology</i> , 2014, 39, 415-424.	5.4	54
155	Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 52, 86-93.	4.8	18
156	Dopamine D4 Receptors in Psychostimulant Addiction. <i>Advances in Pharmacology</i> , 2014, 69, 301-321.	2.0	42
157	Use of candidate gene markers to guide antipsychotic dosage adjustment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 315-320.	4.8	7
158	A Selective Role for Dopamine D4 Receptors in Modulating Reward Expectancy in a Rodent Slot Machine Task. <i>Biological Psychiatry</i> , 2014, 75, 817-824.	1.3	48
159	Dopamine D3 Receptors in the Basolateral Amygdala and the Lateral Habenula Modulate Cue-Induced Reinstatement of Nicotine Seeking. <i>Neuropsychopharmacology</i> , 2014, 39, 3049-3058.	5.4	47
160	Dopamine D3 receptor ligands for drug addiction treatment. <i>Progress in Brain Research</i> , 2014, 211, 255-275.	1.4	47
161	Pharmacotherapies for cannabis dependence. <i>The Cochrane Library</i> , 2014, , CD008940.	2.8	94
162	Dopamine D3 and D4 Receptors as Therapeutic Targets for Nicotine Addiction. , 2014, , 185.		0

#	ARTICLE	IF	CITATIONS
163	Bipolar disorder and co-occurring cannabis use disorders: Characteristics, co-morbidities and clinical correlates. <i>Psychiatry Research</i> , 2013, 209, 459-465.	3.3	96
164	Effects of Nicotine in Animal Models of Drug Addiction Across Species. , 2013, , 89-97.		0
165	The potential role of dopamine D3 receptor neurotransmission in cognition. <i>European Neuropsychopharmacology</i> , 2013, 23, 799-813.	0.7	153
166	Cannabis use and cannabis use disorders among individuals with mental illness. <i>Comprehensive Psychiatry</i> , 2013, 54, 589-598.	3.1	100
167	Cannabis and $\delta^9$ -tetrahydrocannabinol (THC) for weight loss?. <i>Medical Hypotheses</i> , 2013, 80, 564-567.	1.5	47
168	Analysis of CpG SNPs in 34 genes: Association test with suicide attempt in schizophrenia. <i>Schizophrenia Research</i> , 2013, 147, 262-268.	2.0	14
169	Repurposing bupirone for drug addiction treatment. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 251-253.	2.1	11
170	Electrical Stimulation of the Insular Region Attenuates Nicotine-Taking and Nicotine-Seeking Behaviors. <i>Neuropsychopharmacology</i> , 2013, 38, 690-698.	5.4	68
171	Neuropharmacology of Nicotine. , 2013, , 561-571.		2
172	Exploring the Association between Lifetime Prevalence of Mental Illness and Transition from Substance Use to Substance Use Disorders: Results from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). <i>American Journal on Addictions</i> , 2013, 22, 93-98.	1.4	49
173	Gender Differences in Prevalence of Substance Use Disorders among Individuals with Lifetime Exposure to Substances: Results from a Large Representative Sample. <i>American Journal on Addictions</i> , 2013, 22, 7-13.	1.4	76
174	AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking. <i>Journal of Psychopharmacology</i> , 2013, 27, 564-571.	4.0	31
175	Presentation of Smoking-Associated Cues Does Not Elicit Dopamine Release after One-Hour Smoking Abstinence: A [ $^{11}$ C]-(+)-PHNO PET Study. <i>PLoS ONE</i> , 2013, 8, e60382.	2.5	11
176	Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence. <i>Current Drug Targets</i> , 2013, 14, 768-776.	2.1	65
177	Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1265-1274.	2.1	60
178	Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3101-3106.	7.1	110
179	Blockade of Dopamine D4 Receptors Attenuates Reinstatement of Extinguished Nicotine-Seeking Behavior in Rats. <i>Neuropsychopharmacology</i> , 2012, 37, 685-696.	5.4	54
180	Pharmacotherapy of Alcohol Use Disorders and Concurrent Psychiatric Disorders: A Review. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 342-349.	1.9	19

#	ARTICLE	IF	CITATIONS
181	Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 807-811.	1.5	20
182	Self-Reported Psychotic Disorders among Individuals with Substance Use Disorders: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. <i>American Journal on Addictions</i> , 2012, 21, 531-535.	1.4	10
183	Cannabis use and mental health-related quality of life among individuals with anxiety disorders. <i>Journal of Anxiety Disorders</i> , 2012, 26, 799-810.	3.2	31
184	The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. <i>British Journal of Pharmacology</i> , 2012, 165, 2539-2548.	5.4	56
185	A Case of Diagnosing a Long-Standing Psychotic Disorder During Medical Withdrawal. <i>American Journal on Addictions</i> , 2012, 21, 285-286.	1.4	1
186	Nicotine-taking and nicotine-seeking in C57Bl/6J mice without prior operant training or food restriction. <i>Behavioural Brain Research</i> , 2012, 230, 34-39.	2.2	9
187	Gender differences in health-related quality of life among cannabis users: Results from the national epidemiologic survey on alcohol and related conditions. <i>Drug and Alcohol Dependence</i> , 2012, 123, 190-200.	3.2	93
188	Admixture analysis of Age at Onset in Schizophrenia: Genetic Association Study of 45 candidate loci. <i>Schizophrenia Research</i> , 2012, 134, 288-290.	2.0	3
189	Effects of a Selective Cannabinoid CB2 Agonist and Antagonist on Intravenous Nicotine Self Administration and Reinstatement of Nicotine Seeking. <i>PLoS ONE</i> , 2012, 7, e29900.	2.5	61
190	Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. <i>Addiction Biology</i> , 2012, 17, 47-61.	2.6	78
191	Extinction bursts in rats trained to self-administer nicotine or food in 1-h daily sessions. <i>American Journal of Translational Research (discontinued)</i> , 2012, 4, 422-31.	0.0	10
192	Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors. <i>Biological Psychiatry</i> , 2011, 69, 633-641.	1.3	112
193	Dopamine D3 receptor knock-out mice exhibit increased behavioral sensitivity to the anxiolytic drug diazepam. <i>European Neuropsychopharmacology</i> , 2011, 21, 325-332.	0.7	26
194	The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake. <i>British Journal of Pharmacology</i> , 2011, 164, 1652-1660.	5.4	43
195	Prevalence and correlates of major depressive episode in pregnant and postpartum women in the United States. <i>Journal of Affective Disorders</i> , 2011, 135, 128-138.	4.1	211
196	Impact of Hypertension and Body Mass Index on Quality of Life in Schizophrenia. <i>American Journal of Psychiatry</i> , 2011, 168, 552-553.	7.2	2
197	Child Marriage in the United States and Its Association With Mental Health in Women. <i>Pediatrics</i> , 2011, 128, 524-530.	2.1	108
198	Obesity and Cannabis Use: Results From 2 Representative National Surveys. <i>American Journal of Epidemiology</i> , 2011, 174, 929-933.	3.4	139

#	ARTICLE	IF	CITATIONS
199	How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. <i>Tobacco Control</i> , 2011, 20, 338-343.	3.2	61
200	The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 181.	2.1	72
201	Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. <i>Psychiatric Genetics</i> , 2010, 20, 39-43.	1.1	13
202	Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. <i>Human Psychopharmacology</i> , 2010, 25, 582-585.	1.5	16
203	Association of polymorphisms in the <i>BDNF</i> , <i>DRD1</i> and <i>DRD3</i> genes with tobacco smoking in schizophrenia. <i>Annals of Human Genetics</i> , 2010, 74, 291-298.	0.8	54
204	Circadian alteration in neurobiology during protracted opiate withdrawal in rats. <i>Journal of Neurochemistry</i> , 2010, 115, 353-362.	3.9	48
205	Replicated association of the <i>NR4A3</i> gene with smoking behaviour in schizophrenia and in bipolar disorder. <i>Genes, Brain and Behavior</i> , 2010, 9, 910-917.	2.2	22
206	Exposure to Nicotine Produces an Increase in Dopamine D2 <sup>High</sup> Receptors: A Possible Mechanism for Dopamine Hypersensitivity. <i>International Journal of Neuroscience</i> , 2010, 120, 691-697.	1.6	36
207	Noradrenergic $\alpha 1$ Receptors as a Novel Target for the Treatment of Nicotine Addiction. <i>Neuropsychopharmacology</i> , 2010, 35, 1751-1760.	5.4	70
208	Granular Insular Cortex Inactivation as a Novel Therapeutic Strategy for Nicotine Addiction. <i>Biological Psychiatry</i> , 2010, 68, 265-271.	1.3	137
209	Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1412-1418.	4.8	18
210	Effects of chronic caffeine exposure on adenosinergic modulation of the discriminative-stimulus effects of nicotine, methamphetamine, and cocaine in rats. <i>Psychopharmacology</i> , 2009, 203, 355-367.	3.1	31
211	The future of endocannabinoid-oriented clinical research after CB1 antagonists. <i>Psychopharmacology</i> , 2009, 205, 171-174.	3.1	154
212	Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration—comparison with CB1 receptor blockade. <i>Psychopharmacology</i> , 2009, 205, 613-624.	3.1	106
213	Time-Dependent Neuroendocrine Alterations and Drug Craving during the First Month of Abstinence in Heroin Addicts. <i>American Journal of Drug and Alcohol Abuse</i> , 2009, 35, 267-272.	2.1	47
214	Baseline Expression of $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptors Predicts Motivation to Self-administer Nicotine. <i>Biological Psychiatry</i> , 2009, 65, 714-716.	1.3	26
215	Effects of Nicotine in Experimental Animals and Humans: An Update on Addictive Properties. <i>Handbook of Experimental Pharmacology</i> , 2009, , 335-367.	1.8	158
216	Association of a polymorphism in the NRXN3 gene with the degree of smoking in schizophrenia: A preliminary study. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 929-935.	2.6	41

#	ARTICLE	IF	CITATIONS
217	Genetics of dopamine receptors and drug addiction: a comprehensive review. Behavioural Pharmacology, 2009, 20, 1-17.	1.7	350
218	Blocking cannabinoid CB <sub>1</sub> receptors for the treatment of nicotine dependence: insights from preclinical and clinical studies. Addiction Biology, 2008, 13, 239-252.	2.6	97
219	Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats. Neuroscience Letters, 2008, 443, 236-240.	2.1	37
220	Identification of Dopamine D1/D3 Receptor Heteromers. Journal of Biological Chemistry, 2008, 283, 26016-26025.	3.4	216
221	The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction. CNS and Neurological Disorders - Drug Targets, 2008, 7, 468-481.	1.4	32
222	Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3- <sup>2</sup> -Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 482-490.	2.5	132
223	Topiramate does not alter nicotine or cocaine discrimination in rats. Behavioural Pharmacology, 2008, 19, 13-20.	1.7	11
224	Conditioned Place Preference Induced by Licit Drugs: Establishment, Extinction, and Reinstatement. Scientific World Journal, The, 2008, 8, 1228-1245.	2.1	48
225	Validation of an Extracerebral Reference Region Approach for the Quantification of Brain Nicotinic Acetylcholine Receptors in Squirrel Monkeys with PET and 2-18F-Fluoro-A-85380. Journal of Nuclear Medicine, 2007, 48, 1492-1500.	5.0	9
226	Treatment of tobacco dependence: integrating recent progress into practice. Cmaj, 2007, 177, 1373-1380.	2.0	72
227	Dopamine D3receptor ligands for the treatment of tobacco dependence. Expert Opinion on Investigational Drugs, 2007, 16, 45-57.	4.1	38
228	Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Molecular Psychiatry, 2007, 12, 1058-1060.	7.9	16
229	Clonidine attenuates morphine withdrawal and subsequent drug sensitization in rhesus monkeys. Acta Pharmacologica Sinica, 2007, 28, 473-483.	6.1	14
230	Gender and stimulus difference in cue-induced responses in abstinent heroin users. Pharmacology Biochemistry and Behavior, 2007, 86, 485-492.	2.9	70
231	High Reinforcing Efficacy of Nicotine in Non-Human Primates. PLoS ONE, 2007, 2, e230.	2.5	61
232	The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders. CNS and Neurological Disorders - Drug Targets, 2006, 5, 25-43.	1.4	300
233	Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of $\delta^9$ -tetrahydrocannabinol in rats. Behavioural Pharmacology, 2006, 17, 195-199.	1.7	48
234	Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology, 2006, 184, 367-381.	3.1	108

#	ARTICLE	IF	CITATIONS
235	Targeting the Dopamine D <sub>3</sub> Receptor for Treatment of Nicotine Dependence. , 2006, , 199-212.		0
236	Treatment of Nicotine Dependence. , 2006, , 303-318.		0
237	A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning. NeuroReport, 2005, 16, 175-178.	1.2	165
238	Ethanol does not affect discriminative-stimulus effects of nicotine in rats. European Journal of Pharmacology, 2005, 519, 96-102.	3.5	21
239	Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology, 2005, 178, 481-492.	3.1	197
240	Dopamine D <sub>3</sub> Receptor Ligands Block Nicotine-Induced Conditioned Place Preferences through a Mechanism that does not Involve Discriminative-Stimulus or Antidepressant-Like Effects. Neuropsychopharmacology, 2005, 30, 720-730.	5.4	100
241	Cannabinoid CB <sub>1</sub> Receptor Antagonists as Promising New Medications for Drug Dependence. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 875-883.	2.5	275
242	Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency. European Psychiatry, 2005, 20, 431-441.	0.2	57
243	Neuroadaptations to hyperdopaminergia in dopamine D <sub>3</sub> receptor-deficient mice. Life Sciences, 2005, 76, 1281-1296.	4.3	55
244	Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends in Pharmacological Sciences, 2005, 26, 287-293.	8.7	93
245	The dopamine D receptor and drug dependence: Effects on reward or beyond?. Neuropharmacology, 2005, 49, 525-541.	4.1	166
246	Brain-Derived Neurotrophic Factor And The Plasticity Of The Mesolimbic Dopamine Pathway. International Review of Neurobiology, 2004, 59, 425-444.	2.0	39
247	Rimonabant, a CB <sub>1</sub> antagonist, blocks nicotine-conditioned place preferences. NeuroReport, 2004, 15, 2139-2143.	1.2	174
248	Role of DRD <sub>3</sub> in morphine-induced conditioned place preference using drd3-knockout mice. NeuroReport, 2004, 15, 2245-2249.	1.2	46
249	Increased dopamine D <sub>3</sub> receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse, 2003, 47, 176-183.	1.2	139
250	Disruption of nicotine conditioning by dopamine D <sub>3</sub> receptor ligands. Molecular Psychiatry, 2003, 8, 225-230.	7.9	81
251	Role of the dopamine D <sub>3</sub> receptor in reactivity to cocaine-associated cues in mice. European Journal of Neuroscience, 2002, 15, 2016-2026.	2.6	162
252	Dopamine D <sub>3</sub> Receptors Expressed by All Mesencephalic Dopamine Neurons. Journal of Neuroscience, 2000, 20, 8677-8684.	3.6	308

#	ARTICLE	IF	CITATIONS
253	Dopamine D3 receptor agents as potential new medications for drug addiction. <i>European Psychiatry</i> , 2000, 15, 140-146.	0.2	89